US Pharma MarketingBraveheart files for IPO to fund Phase 3 of Hengrui
Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Biotechs are sprinting to the IPO queue.
In the industry's fourth IPO filing in two weeks, Braveheart Bio is seeking a Nasdaq listing to fuel Phase 3 testing of a cardio drug that could potentially ...
Source: Endpoints News